Klin Farmakol Farm. 2009;23(3):143-146

New Looks at Osteoporosis Therapy

prof. MUDr. Vladimír Palička CSc

Ústav klinické biochemie a diagnostiky FN a LF UK Hradec Králové

Burden of postmenopausal osteoporosis requests active prevention as well as highly precise and evidence-based stratification of individual

risk of fracture. Based on estimated risk adequate treatment should be selected. T-score, reflecting bone mineral density in selected

areas of skeleton, only, is going to be insufficient marker. FRAX calculator of individual fracture risk in the next ten years, supported by

WHO and IOF, looks promising in that aspect. The great advantage of FRAX is considering the main risk factors together with BMD.

Challenging question is long-lasting therapy, its effects, advantages and disadvantages. Data are insufficient up to now to decide for

stopping or continuing the therapy. Question is difficult to resolve; up to now there are not decisive data for stopping therapy.

New therapeutics will be focused not only on osteoclasts and/or osteoblasts and their activity. Stem cells and their differentiation will

be target of scientific teams. Regulation of mesenchymal stem cells differentiation into adipocytes and/or osteoblasts is close to preclinical

applications.

Keywords: postmenopausal osteoporosis, stem cells, fracture risk.

Published: November 6, 2009  Show citation